BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25130081)

  • 1. Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan.
    Tiseo M; Buti S; Boni L; Mattioni R; Ardizzoni A
    Lung Cancer; 2014 Oct; 86(1):91-5. PubMed ID: 25130081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period.
    Hansen O; Sørensen P; Hansen KH
    Lung Cancer; 2010 Apr; 68(1):111-4. PubMed ID: 19535164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
    Biernacka B; Krawczyk P; Buczkowski J; Siwiec A; Perzyło K; Milanowski J
    Pneumonol Alergol Pol; 2010; 78(3):192-202. PubMed ID: 20461687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.
    Ardizzoni A; Tiseo M; Boni L
    Eur J Cancer; 2014 Sep; 50(13):2211-8. PubMed ID: 24981975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis.
    Hermes A; Waschki B; Reck M
    Respir Med; 2012 Jun; 106(6):900-4. PubMed ID: 22405607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
    Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
    Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease.
    Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Uehara N; Matsuura Y; Tamiya M; Morishita N; Higashiguchi M; Tsumori T; Kawase I
    J Chemother; 2011 Dec; 23(6):367-70. PubMed ID: 22233823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
    von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
    J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
    Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
    Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
    Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
    Lv C; Liu X; Zheng Q; Chen H; Yang X; Zhong J; Wang Y; Duan J; Wang Z; Bai H; Wu M; Zhao J; Wang J; Wang Z; An T; Zhuo M
    Thorac Cancer; 2018 Sep; 9(9):1166-1173. PubMed ID: 30058109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.
    Yang Y; Sun N; Sun P; Zhang L
    Anticancer Res; 2017 Aug; 37(8):4681-4686. PubMed ID: 28739771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
    Garassino MC; Torri V; Michetti G; Lo Dico M; La Verde N; Aglione S; Mancuso A; Gallerani E; Galetta D; Martelli O; Collovà E; Fatigoni S; Ghidini A; Saggia C; Bareggi C; Rossi A; Farina G; Thatcher N; Blackhall F; Lorigan P; Califano R
    Lung Cancer; 2011 Jun; 72(3):378-83. PubMed ID: 20950888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features and prognosis analysis of small-cell lung cancer complicated with hyponatremia].
    Ma F; Liu X; Hu C; Huang M
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 36(1):64-7. PubMed ID: 21311141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department].
    Hureaux J; Alizon C; Urban T
    Rev Mal Respir; 2012 May; 29(5):680-7. PubMed ID: 22682594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patients.
    Nagy-Mignotte H; Guillem P; Vignoud L; Coudurier M; Vesin A; Bonneterre V; Toffart AC; Sakhri L; Brambilla C; Brambilla E; Timsit JF; Moro-Sibilot D;
    Lung Cancer; 2012 Oct; 78(1):112-20. PubMed ID: 22795703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.